Anesth Prog. 2024 Jul 8;71(2):58-75. doi: 10.2344/22-00033.
This study aimed to establish which anesthetic agents are associated with minimized adverse outcomes during laryngeal mask airway (LMA) insertion.
Databases were searched for randomized controlled trials (RCTs) with American Society of Anesthesiologists I or II adult patients (≥15 years of age) receiving general anesthesia (GA) with an LMA. Propofol only was the comparator to other anesthetics used during LMA insertion. The primary outcome was prolonged apnea, and secondary outcomes were adverse airway events, LMA insertion failure, inadequate depth of anesthesia, and hemodynamic events. A network meta-analysis was conducted to estimate the treatment effects (odds ratios, 95% credible intervals, and surface under the cumulative ranking curve [SUCRA]).
A total of 28 anesthetic combinations used on 4695 patients for GA induction and LMA insertion were examined across 53 RCTs. Overall, there was an apnea incidence rate of 33.3% (849 of 2548) with a mean time of 3.74 ± 3.56 minutes (n = 3091). Propofol + dexmedetomidine had the highest overall summed score of SUCRA ranks in reducing adverse outcomes (apnea incidence: SUCRA = 37%, apnea time: SUCRA = 66%, airway adverse event: SUCRA = 67%, insertion failure: SUCRA = 73%, inadequate depth of anesthesia: SUCRA = 84%). In comparison among all propofol combinations, propofol alone ranked lowest for overall summed score of SUCRA in reducing adverse outcomes (apnea incidence: SUCRA = 47%, apnea time: SUCRA = 71%, airway adverse event: SUCRA = 9%, insertion failure: SUCRA = 20%, inadequate depth of anesthesia: SUCRA = 9%).
All anesthetic combinations, other than those with thiopental, reduced adverse outcomes as compared with propofol alone. The combination of propofol and dexmedetomidine infused over 10 minutes ranked as the most effective for reducing adverse outcomes during LMA insertion.
本研究旨在确定在喉罩气道(LMA)置入期间使用哪种麻醉剂可将不良结果的风险降到最低。
检索数据库中包含美国麻醉医师协会(ASA)I 级或 II 级成年患者(≥15 岁)全身麻醉(GA)并置入 LMA 的随机对照试验(RCT)。仅使用丙泊酚作为 LMA 置入期间使用其他麻醉剂的对照。主要结局是延长的呼吸暂停,次要结局是不良气道事件、LMA 置入失败、麻醉深度不足和血流动力学事件。进行网络荟萃分析以评估治疗效果(比值比、95%可信区间和累积排序曲线下面积 [SUCRA])。
在 53 项 RCT 中,共检查了 4695 例患者接受 GA 诱导和 LMA 置入时使用的 28 种麻醉组合。总体上,2548 例中有 33.3%(849 例)发生呼吸暂停,平均时间为 3.74±3.56 分钟(n=3091)。在降低不良结局方面,丙泊酚+右美托咪定的总体 SUCRA 等级综合评分最高(呼吸暂停发生率:SUCRA=37%,呼吸暂停时间:SUCRA=66%,气道不良事件:SUCRA=67%,置入失败:SUCRA=73%,麻醉深度不足:SUCRA=84%)。与所有丙泊酚组合相比,在降低不良结局的总体 SUCRA 等级综合评分中,单独使用丙泊酚的排名最低(呼吸暂停发生率:SUCRA=47%,呼吸暂停时间:SUCRA=71%,气道不良事件:SUCRA=9%,置入失败:SUCRA=20%,麻醉深度不足:SUCRA=9%)。
除硫喷妥钠外,所有麻醉组合均能降低不良结局的发生风险。丙泊酚与右美托咪定输注 10 分钟以上的组合在降低 LMA 置入期间不良结局方面的效果最佳。